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Malignancy must be considered in the management of adrenal lesions, including those incidentally identified
on imaging studies. Adrenocortical carcinomas (ACCs) are rare tumors with an estimated annual incidence of
0.7–2 cases per year and a worldwide prevalence of 4–12 cases per million/year. However, a much higher
incidence of these tumors (415 times) has been demonstrated in south and southeastern Brazil. Most ACCs
cause hypersecretion of steroids including glucocorticoids and androgens. ACC patients have a very poor
prognosis with a 5-year overall survival (OS) below 30% in most series. Pheochromocytoma or paraganglioma
(PPGL) is a metabolically active tumor originating from the chromaffin cells of the adrenal medulla. The
incidence of PPGL is 0.2 to 0.9 cases per 100,000 individuals per year. Pheochromocytomas are present in
approximately 4-7% of patients with adrenal incidentalomas. Classically, PPGL manifests as paroxysmal attacks
of the following 4 symptoms: headaches, diaphoresis, palpitations, and severe hypertensive episodes. The
diagnosis of malignant PPGL relies on the presence of local invasion or metastasis. In this review, we present the
clinical and biochemical characteristics and pathogenesis of malignant primary lesions that affect the cortex and
medulla of human adrenal glands.
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’ INTRODUCTION
Human adrenal glands can be affected by several
malignant conditions. Indeed, malignancy must be consid-
ered in the management of adrenal lesions, including those
incidentally identified on imaging studies (adrenal inciden-
talomas). Adrenal incidentalomas are identified in 1–4% of
abdominal imaging studies, and the incidence of adrenal
incidentaloma increases with age. In medical series, most
adrenal incidentalomas are adenomas (80%), and only 8%
are carcinomas. Therefore, the incidental discovery of an
adrenal mass could be considered an opportunity to offer a
curative approach for malignant lesions (1).
Adrenocortical carcinomas (ACCs) are rare tumors with an
estimated annual incidence of 0.7–2 cases per year and a
worldwide prevalence of 4–12 cases per million/year (2).
However, a much higher incidence of adrenal tumors (415
times) has been demonstrated in the pediatric population
in south and southeastern Brazil, and these tumors are
associated with a specific germline mutation in TP53 (3,4).
These malignant tumors can be diagnosed by endocrine
signs of steroid excess, compression symptoms due to tumor
growth or during evaluation of adrenal incidentalomas. The
majority of adrenal tumors secrete excess cortisol, although
this cortisol hypersecretion can be subclinical. ACC patients
have a very poor prognosis with a 5-year overall survival
(OS) below 30% in most series. Despite this unfavorable
outcome, some patients are cured after surgical removal, and
others have relatively slow metastatic progression. The recent
discovery of genetic alterations underlying the pathogenesis of
ACC have led to the identification of ACC subgroups with
dismal prognoses (5).
Pheochromocytoma or paraganglioma (PPGL) is a meta-
bolically active tumor originating from the chromaffin cells
of the adrenal medulla. The incidence of PPGL is 0.2 to 0.9
cases per 100,000 individuals per year. Pheochromocytomas
are present in approximately 4-7% of patients with adrenal
incidentalomas. Classically, PPGL manifests as paroxysmal
attacks of the following 4 symptoms: headaches, diaphoresis,
palpitations, and severe hypertensive episodes. The diag-
nosis of malignant PPGL relies on the presence of local
invasion or metastasis. The most common sites of metastasis
include bones, lymph nodes and the liver. In this review, we
present the clinical and biochemical characteristics and
pathogenesis of malignant primary lesions that affect the
cortex and medulla of human adrenal glands (6).
Adrenocortical carcinoma
ACC presents a bimodal distribution, with the first peak in
childreno5 years and the second (7) peak during the 4th and
5th decades of life and a slight predominance in women (2,8).DOI: 10.6061/clinics/2018/e756s
Copyright & 2018 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on April 24, 2018. Accepted for publication
on October 23, 2018
Commemorative Edition: 10 years of ICESP
1
REVIEW ARTICLE
In the pediatric population, only 25 new cases are diagnosed
each year in the USA. In south and southeastern Brazil,
approximately 78% of children and 13% of adults with
adrenal tumors harbor a specific germline mutation
(p.R337H) of the p53 tumor suppressor (9,10). A founder
effect has been demonstrated in the great majority of pedia-
tric Brazilian patients with adrenocortical tumors caused by
this p53 mutation (11).
Virilization syndrome is the most frequent presentation of
adrenal tumors during childhood. Hypercortisolism can be
associated with androgen overproduction, mainly of dehy-
droepiandrosterone sulfate (DHEAS) and testosterone, lead-
ing to gonadotropin-independent precocious puberty (3,12).
In adults, cortisol hypersecretion is the most common
hormone disorder. Adult ACC can also be associated with
virilization alone or a mixed syndrome (virilization and
Cushing’s syndrome). Estrogen and aldosterone overproduc-
tion are highly uncommon (2). Although uncommon, patients
with advanced disease can present with cachexia and body
weight loss (13).
Most ACCs are sporadic, but some inherited disorders
are associated with a high incidence of ACC, such as
Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syn-
drome (BWS), Lynch syndrome (LS) and multiple endocrine
neoplasia syndrome type 1 (MEN1) (14) (Table 1). LFS is a
cancer predisposition syndrome usually caused by an
inherited TP53 gene mutation and is characterized by a high
occurrence of sarcomas, early onset breast cancer, brain cancer
and leukemia (15). ACC accounts for approximately 3% to
10% of LFS-associated cancers (5).
Somatic TP53 mutations have been identified in 25–35% of
sporadic ACCs. Nevertheless, these mutations represent a
late event during carcinogenesis and have been associated
with larger tumors and more advanced disease (14). Somatic
mutations in the TP53 gene are a predictor of poor overall
survival in adults with ACC (16).
The overexpression of IGF2 is one of the most important
mechanisms of adrenocortical tumorigenesis. IGF2 is a potent
in vitro growth promoter of adrenal cortex carcinoma cell lines
(17). The IGF2 gene is located on chromosome 11p15 and
encodes a growth factor that is expressed only through the
inherited paternal allele, while the maternal allele is silenced.
Genetic or epigenetic alterations in the 11p15 region may alter
the expression of the CDKN1C, IGF2 andH19 genes, which are
structurally organized in a cluster, increasing IGF2 expression
and inactivating the CDKN1C and H19 genes, which are a
negative cell cycle regulator and a transcriptional repressor of
IGF2, respectively. BWS is an example of epigenetic alterations
in the 11p15 region (18). Macrosomia, macroglossia, viscer-
omegaly, neonatal hypoglycemia, and ear and abdominal wall
abnormalities characterize BWS. Children with BWS also have
a high risk of developing Wilms’ tumors, hepatoblastomas,
rhabdomyosarcomas, and ACCs (19).
The gene expression profiles of 94 ACCs in adults demon-
strated that the DGL7 and PINK1 genes were differentially
expressed between recurrent and nonrecurrent tumors (20).
Furthermore, the difference between BUB1B and PINK1 gene
expression was a significant predictor of OS in adults. The
prognostic importance of the combined expression of these
genes was subsequently validated in adult ACC patients
from our institution but not in pediatric patients (21).
Diagnostic evaluation
Autonomous cortisol secretion may be identified in almost
70% of patients with ACC, although this finding is clinically
unapparent in many patients (22). The European Network
for the Study of Adrenal Tumors (e-mail: ENS@T) has sug-
gested a comprehensive hormone investigation for cortisol
oversecretion (1 mg dexamethasone supression test at 23 h),
basal cortisol and ACTH levels, and free 24-h urinary cortisol
concentrations), excess of sexual steroid and steroid pre-
cursors [DHEA-S, 17-OH-progesterone, androstenedione,
testosterone and 17-b-estradiol levels (only in men and
postmenopausal women)], primary aldosteronism (aldoster-
one and renin levels in patients with hypertension and/or
hypokalemia) and pheochromocytoma (total 24-h urinary
metanephrine or plasma free metanephrine concentrations)
(23). In our center, 11-deoxycortisol levels are also evaluated
in patients with masses suspicious for malignancy due to the
prognostic value of this parameter.
Most ACCs are large, heterogeneous lesions with irregular
contrast uptake (Table 2). On CT, ACC is characterized by a
precontrast density greater than 10 Hounsfield units (HU),
indicating low lipid content, and absolute contrast wash-
out o40% to 50% (1). In fact, malignant primary adrenal
lesions usually have a precontrast density430 HU. Magnetic
resonance imaging (MRI) with gadolinium has the same
accuracy as CT but may be superior for evaluating vascular
invasions. Positron emission tomography (PET) using 18F-
fluorodeoxyglucose (FDG) coupled to a CT scan is helpful for
Table 1 - Inherited disorders associated with ACC [Adapted from Patsy et al. (14).
Syndrome* Gene mutation General population
prevalence
Prevalence in
ACC patients
Other characteristics
LFS TP53 1:20.000 3–7% (adults) 50–80% (children) Sarcomas, choroid plexus tumors, cerebral tumors,
breast cancer, leukemia, lymphoma.
MEN1 MEN1 1:30 000 1-2% (adults) Neuroendocrine tumors, pituitary tumors, parathyroid
hyperplasia, adrenal adenomas, angiofibromas.
Lynch MSH2, MSH6,
MLH1, PMS2
1:440 3% (adults) Colorectal cancer, endometrial cancer, ovarian cancer,
pancreatic cancer, brain tumors.
BWS IGF2, CDKN1C 1:13.000 Very rare (children) Wilms’ tumors, hepatoblastomas, adrenal adenomas,
macrosomia, macroglossia, omphaloceles.
FAP APC 1:30.000 o1% Colonic polyposis, colorectal cancer, desmoid tumors,
thyroid cancer, adrenal adenomas, congenital retinal
hyperplasia, epidermoid cysts.
NF1 NF1 1:3.000 o1% Pheochromocytomas, cafe´-au-lait spots, neurofibromas,
optic gliomas, Lisch nodules, skeletal abnormalities.
* LFS: Li-Fraumeni syndrome, MEN1: Multiple endocrine neoplasia type 1, BWS: Beckwith-Wiedemann syndrome, FAP: Familial adenomatous polyposis,
NF1: Neurofibromatosis type 1.
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evaluating adrenal tumors. Malignant lesions have high
metabolic activity leading to high FDG uptake. Adrenal
adenomas usually have low FDG uptake. However, phe-
ochromocytomas, adrenal metastases and rarely adenomas
(especially those with high hormonal activity) can have
high metabolic activity, resulting in false positives (1).
A careful histopathological evaluation is critical for the
correct diagnosis of adrenal tumors, especially for neoplasms
localized to the adrenal gland (24). The first step of the
analysis consists of evaluating several macroscopic para-
meters, including tumor size and weight, capsule integrity,
and the presence of hemorrhage or necrosis. The second step
is to analyze several microscopic aspects that, together,
confirm the diagnosis (25). The Weiss score comprises nine
histopathological parameters: three are related to tumor
structure (presence of necrosis, diffuse architecture and per-
centage of clear cells), three are related to cellular structure
(atypical mitoses, number of mitoses and high nuclear grade
(Fuhrman 3-4)), and three are related to invasion (vascu-
lar invasion, sinusoidal invasion and capsular invasion).
According to the Weiss system, a tumor of the adrenal cortex
is defined as carcinoma when it presents with at least three of
these criteria (26).
Ki67 is a protein expressed in all cell cycle phases except
G0 and represents a validated cell proliferation index. Ki67 is
an important prognostic factor for localized ACCs. When
evaluated by immunohistochemistry, a Ki67 index410% can
differentiate tumors with a high risk of recurrence that are
potentially candidates for adjuvant therapy. High levels of
Ki67 have also been associated with worse OS in patients
with advanced disease and can help in decision-making
regarding treatment (27).
Staging
The staging system proposed by the e-mail: ENS@T is the
best available system, as this system clearly identifies patient
prognosis (22). The e-mail: ENS@T system classifies tumors
as stage I or II when they are restricted to the gland and
o5 cm or 45 cm in size, respectively. Stage III is deter-
mined by adjacent tissue invasion, neoplastic thrombus to
the vena cava or renal vein, or regional lymph node metastasis.
In addition, stage IV is determined by the presence of distant
metastasis.
In 2015, the e-mail: ENS@T proposed that metastatic ACC
should be classified into three subgroups (IVa, IVb and IVc).
Subgroup IVa included patients with regional lymph node
involvement and patients with one or 2 metastatic organs,
including lymph nodes. Subgroups IVb and IVc included
patients with 3 or more metastatic organs, respectively.
Furthermore, some factors associated with worse prognoses
are represented in the GRAS score (Grade: Weiss46 and/or
Ki67 420%; R status: uncomplete resection of the primary
tumor; Age: age greater than or equal to 50 years; and
Symptoms: symptoms related to the tumor or hormonal
production). The combination of the e-mail: ENS@T classifi-
cation system and the GRAS score have a good correlation with
patient prognosis in stage III and IV adrenal carcinomas (28).
Staging is the most important prognostic factor for ACC
patients. There is still considerable variability among pub-
lished studies about the likelihood of recurrence and survival.
In recent studies, patients with stage I disease had an
estimated 5-year OS rate of 66% to 82%. In patients with
stage II and III disease, the 5-year OS rate varied from 58% to
64% and 24% to 50%, respectively. In patients with stage IV
disease, the estimate 5-year OS rate decreased significantly to
0% to 17%. Other predictors of poor prognosis are older age at
diagnosis, mixed syndrome (cortisol and androgen produc-
tion) or estrogen-producing ACC, and incomplete resection,
either with gross (R2) or microscopic residual disease (R1) (28).
Treatment
Complete surgical resection is the most effective treatment
(2). Unfortunately, complete resection is achievable only for
locally restricted disease (stages I, II and some stage III
tumors) (29). Biopsy of adrenal masses is indicated to
confirm the anatomopathological diagnosis of noncortical
adrenal lesions or if surgery is not the initial approach,
but the anatomopathological diagnosis is necessary before
initiating systemic therapy for advanced metastatic disease.
Experienced surgeons should perform surgery with cura-
tive intent to avoid incomplete resections and/or rupture of
the tumor capsule. A laparoscopic approach is indicated for
tumors o6 cm in size without signs of local invasion and
should only be performed in highly experienced centers.
En bloc resection is recommended when there is adjacent
tissue invasion (29). The presence of a vena cava thrombus is
Table 2 - Imaging characteristics of the most prevalent tumoral lesions in the adrenal gland (23).
Adrenal Adenoma
Frequently o4 cm, homogeneous and well-defined in shape
CT: density o10 HU* without contrast; 40 to 50% washout or density
o35 HU 10-15 min after contrast injection
MRI: homogenously isointense or hypointense on T2-weighted sequences.
Adrenal Carcinoma
Frequently 46 cm, heterogeneous and irregularly shaped.
CT: density 410 HU without contrast; less than 40 to 50% washout or density
435 HU 10-15 min after contrast injection
MRI: hyperintense on T2-weighted sequences; o30% loss of signal intensity on out-of-phase images.
Metastasis
Heterogeneous lesions, frequently affecting both glands, with contrast enhancement.
CT and MRI: similar findings to adrenal carcinomas
Pheochromocytoma
Heterogeneous and dense lesions with intense contrast enhancement.
MRI: hyperintense on T2-weighted sequences; o30% loss of signal intensity on out-of-phase images.
Myelolipoma
CT: Import lipid content with very low density
MRI: similar behavior as lipid content in the subcutaneous tissues and retroperitoneum on phase-sequences.
*Hounsfield unit.
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compatible with complete resection, but extracorporeal
circulation might be necessary. Prophylactic lymphadenect-
omy is not clearly associated with better prognosis and is not
mandatory (29).
Patients with a suspected adrenal mass and abnormal
glucocorticoid secretion, whether clinical or subclinical,
should receive exogenous glucocorticoid replacement dur-
ing the perioperative and postoperative periods to prevent
acute adrenal insufficiency after resection of the tumor. We
recommend that 100 mg of intravenous (i.v) hydrocortisone
be administered at the time of anesthetic induction followed
by 50 mg of i.v hydrocortisone every 8 h for approximately
2 days, after which hydrocortisone replacement can be
provided by oral therapy.
After a complete surgical resection, patients should be
followed up every 3 months. The follow-up of these patients
should include a complete physical examination, hormonal
evaluation and complete radiological evaluation including
CT of the thorax and abdomen. After 2-3 years of follow-up
without recurrence, imaging studies can be performed every
6 months (22).
Unfortunately, a large number of patients still experience
disease recurrence even after complete surgical resection.
Adjuvant mitotane treatment is associated with increased
disease-free survival but not OS (30). There are discussions
regarding how long mitotane should be used in this setting,
but most specialists agree that 2 years should be the
minimum period. However, mitotane is toxic, and many
patients do not tolerate treatment for long periods. Thus,
adjuvant mitotane should be considered mainly for high-risk
patients (stage III disease or tumors 48-10 cm in size, those
with high mitotic rates or a proliferative index Ki67 410%,
and those with microscopic evidence of vascular or capsular
invasion). The benefit of mitotane in the low/intermediate-
risk group of patients is currently being evaluated in the
multicentric, prospective, phase III ADIUVO trial (2).
Adjuvant radiation therapy of the adrenal bed is associated
with a reduction in local disease recurrence only, with no
benefits in OS (31). Few retrospective studies have shown
that radiation therapy may improve local control after
surgical resection in patients with localized ACCs (31-34).
Therefore, the indications for adjuvant radiation therapy are
still being debated.
Mitotane is the only available adrenolytic drug for ACC
treatment. In addition to its use in the adjuvant setting,
mitotane is associated with a 30% objective response rate
among patients with metastatic disease in retrospective
studies. Mitotane inhibits steroidogenesis and controls hor-
mone excess syndromes. Treatment should be initiated at a
dose of 1.5 g/d, with a progressive increase up to 5-6 g/d.
The goal during treatment is to achieve plasma mitotane
levels between 14 and 20 mcg/mL (35). Plasma mitotane
concentrations greater than 20 mcg/mL are associated with
significant toxicity, including neurological effects (lethargy,
somnolence, ataxia, and polyneuropathy, among others).
Plasma concentration monitoring should be performed every
4 to 6 weeks during the initiation of treatment. Most patients
require at least 2 to 3 months of treatment to achieve thera-
peutic levels (35).
The most common side effects of mitotane are gastro-
intestinal and are characterized by anorexia, nausea, vomiting,
diarrhea and abdominal discomfort. Mitotane also increases
the concentrations of cortisol-binding globulin hormone (CBG),
steroid-binding globulin (SHBG), and thyroxine-binding
globulin (TBG). Furthermore, mitotane may impair pitui-
tary gland function by reducing TSH secretion with
consequent hypothyroidism and gonadal function causing
hypergonadotropic hypogonadism (23). Cholesterol and
triglyceride levels should be monitored regularly due to
increases in LDL-cholesterol, HDL-cholesterol and trigly-
cerides (35). In the presence of persistently elevated lipid
concentrations, statin use is indicated. Statins that are not
metabolized by CYP3A4 are preferable, such as rosuvas-
tatin and pravastatin.
Notably, mitotane induces adrenal insufficiency due to the
inhibition of steroidogenesis enzymes. As mitotane also
increases peripheral cortisol metabolism and increases CBG
concentrations, patients on glucocorticoid replacement ther-
apy need higher replacement doses. The indications for
mineralocorticoid replacement depend on potassium and
renin levels (35).
Chemotherapy has been used but with limited results.
Recently, the first randomized phase III trial with metastatic
ACC patients compared to two promising protocols (etopo-
side, doxorubicin, cisplatin and mitotane [EDPM] vs.
streptozotocin and mitotane) (36). EDPM proved to be
superior in terms of the objective response rate (20.5% vs.
7.9%) and progression-free survival (5 m vs. 2.1 m) but was
not superior in terms of OS. This study established EDPM
as the most evidence-based first-line therapy but also
highlighted the necessity for better therapies to be devel-
oped for ACC patients (36). A phase I study of imatinib,
dacarbazine, and capecitabine included 6 patients with adrenal
cancer (37). Among ACC patients, one of the 6 patients
presented a partial response with a progression-free survival
of 8.8 months (37).
Several phase II studies have investigated molecular target
therapies in patients with advanced ACC: inhibitors of epi-
dermal growth factor receptor (EGFR; erlotinib and gefiti-
nib), mammalian target of rapamycin (mTOR; everolimus),
platelet-derived growth factor receptor (PDGFR) and c-KIT
(imatinib), and vascular endothelial growth factor (VEGF;
bevacizumab) and antibodies against insulin-like growth
factor 1 receptor (IGF-1R; figitumumab and cixutumumab)
did not demonstrate any effectiveness (38). Linsitinib, an oral
IGF-1R inhibitor, was evaluated in a randomized placebo-
controlled phase III study including 139 patients with
advanced ACC (39). Unfortunately, linsitinib did not improve
progression-free survival or OS when compared to placebo.
Surgical debulking can be considered in patients with
nonresectable tumor masses, limited sites of metastasis or
clinical findings of extreme hormonal excess that prove to
be refractory to clinical treatment. Although not completely
proven, surgical debulking might offer survival advantages
for patients with metastatic disease (29).
Malignant pheochromocytoma and paraganglioma
Pheochromocytomas and paragangliomas (PPGLs) are
neuroendocrine tumors derived from chromaffin cells of
the adrenal medulla (called pheochromocytomas) or from
the sympathetic or parasympathetic autonomic ganglia
(paragangliomas). Approximately 80 to 85% of chromaffin-
cell tumors are pheochromocytomas, whereas 15 to 20% are
paragangliomas. In this review, pheochromocytomas and
paragangliomas are referred to as PPGLs. These tumors
account for up to 0.6% of cases of adult hypertension and
1% of cases of pediatric hypertension (6). More than 30% of
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patients with PPGLs have a hereditary predisposition, and up
to 50% of patients with metastatic disease have hereditary
germline mutations. To date, at least 14 tumor susceptibility
genes have been described (6,40,41). These susceptibility
genes can be divided into two clusters: cluster 1 tumors
include those with mutations of genes encoding the von
Hippel-Lindau (VHL) suppressor, the four subunits of the
succinate dehydrogenase complex (SDHA, SDHB, SDHC,
and SDHD), and less commonly, the enzyme responsible
for flavination of the SDHA subunit (SDHAF2), fumarate
hydratase, malate dehydrogenase 2, and prolyl hydroxy-
lases 1 and 2. These genetic alterations result in stabilization
of hypoxia-inducible factors and activation of the hypoxia
signaling pathways. Cluster 2 includes tumors with mutations
of the neurofibromatosis type 1 (NF1) tumor suppressor gene,
the rearranged during transfection (RET) proto-oncogene,
genes encoding transmembrane protein 127 (TMEM127) and
MYC-associated factor X (MAX) (6,40,41) (Table 3). We recom-
mend genetic screening for PPGL patients in the following
situations: those with bilateral pheochromocytomas, all patients
with paragangliomas, those with malignant PPGLs and
patients younger than 45 years with isolated pheochro-
mocytomas (6,42).
Diagnosis of malignant PPGLs
The early diagnosis of PPGLs is crucial for several reasons.
Most PPGLs hypersecrete catecholamines and are associa-
ted with increased cardiovascular morbidity and mortality.
Additionally, PPGLs may cause mass-effect symptoms and
have malignant potential. Additionally, familial counseling
may result in earlier diagnosis and treatment of asympto-
matic carriers. Malignancy is defined by metastases in non-
chromaffin tissue. Malignancy in PPGLs affects between 10
and 17% of patients, but the prevalence of such malignancy
depends mostly on the germline mutation underlying PPGL
pathogenesis (6). Approximately 35% of patients present with
synchronous metastases, whereas 65% of patients develop
metachronous metastases at a median of 5.5 years after
diagnosis (43). Patients who are young and those with larger
tumors (46 cm), positive genetic testing (especially SDHB)
or paragangliomas have an increased risk of metastasis and
require long-term follow-up. Patients with negative genetic
testing and pheochromocytomas o4 cm in size have a lower
risk of malignancy (44). In a recent study, 76% of patients
with malignant PPGLs had germline mutations in suscept-
ibility genes for PPGL (SDHB, 44%; SDHD, 8%; VHL, 12%;
NF1, 12%; and RET, 0%) (44). TMEM127 and MAX muta-
tions have also been described in patients with malignant
PPGLs (45).
Biochemical investigation of PPGL patients should include
measurement of plasma free metanephrine or 24-h urinary
fractionated metanephrine concentrations using liquid chro-
matography with mass spectrometry. Total 24-h urinary
catecholamine concentrations should also be measured to
avoid missing isolated dopamine-producing PPGLs. To
measure plasma metanephrines, blood should be drawn
with the patient in the supine position. Topographical
investigation for PPGLs should be performed only after the
biochemical diagnosis of PPGLs. Imaging studies should be
initiated with abdominal CT or MRI (6).
The sensitivity of 123 I-metaiodobenzylguanidine (MIBG)
scintigraphy is approximately 80% for pheochromocytomas
and 50% for paragangliomas (46,47). 123 I-MIBG is recom-
mended in patients with an increased risk for metastatic
disease due to the large size of the primary tumor, positive
genetic testing or extra-adrenal, multifocal or recurrent
disease (6). For high-risk patients, we also recommend chest
CT to identify lung metastasis. Recent studies have demon-
strated that 123I-MIBG SPECT is similar to PET-CT using
18F-FDG to detect PPGLs (48). 123I-MIBG is inferior to
18F-FDG-PET or somatostatin receptor imaging for paragan-
gliomas or metastatic disease associated with SDHx-related
tumors (49).
Treatment
All patients with a hormonally functional PPGLs should
be treated with a-adrenergic receptor blockers to prevent
perioperative cardiovascular complications. Preoperative
medical treatment for PPGL patients should be initiated at
least 14 days before surgery to allow adequate time to
normalize blood pressure and heart rate. Since PPGL patients
have severe vasoconstriction with volume depletion, treat-
ment should include a high-sodium diet and fluid intake to
prevent severe hypotension after tumor removal (6). Selective
a1-receptor blockers (extended-release prazosin or doxazo-
sin) to control blood pressure and adrenergic symptoms are
recommended. The dose should be started at 1 mg twice
daily and titrated to 10-14 mg/d. Preoperative b-adrenergic
receptor blockers are indicated to control tachycardia after
the administration of a-adrenergic receptor blockers. The use
of b-adrenergic receptor blockers should not be initiated
before a-adrenoceptor blockers because the unopposed
stimulation of a-adrenergic receptors can induce adrenergic
crises. If the patient has been a-blocked and remains
hypertensive, calcium blocker channels should be added.
The treatment goal is a blood pressure of less than
130/80 mmHg while seated and greater than 90 mmHg
systolic while standing. Furthermore, a-receptor blockers
should be discontinued 12h before surgery to prevent
refractory hypotension after tumor removal. We recom-
mend a-blockade even in normotensive patients if the
PPGL is biochemically active.
The treatment of choice for localized PPGLs is laparoscopic
resection. Open resection is indicated for tumors 46 cm in
size or invasive PPGLs to ensure complete tumor resection,
prevent tumor rupture, and avoid local recurrence. Patients
with pheochromocytomas larger than 6 cm or paraganglio-
mas of any size and/or those who are carriers of SDHB
mutations need imaging studies to localize metastatic disease
(50). For high-risk patients, we recommend abdominal and
pelvic MRI and chest CT every 4-6 months during the first
2-3 years and then annually. Ideally, a whole-body scan, such
Table 3 - Frequency of germline mutations in 519 adults with
PPGLs and risk of malignancy (42).
Genes Frequency (%) Risk of malignancy in
mutation carriers (%)
Cluster 1
VHL 10 6
SDHB 17 69
SDHD 11 31
SDHC 1 17
Cluster 2
RET 9 4
NF1 4 5
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as an 18F-FDG-PET scan, should be performed for patients
with SDHB-positive tumors every 1 or 2 years in addition to
routine imaging evaluations.
In a recent retrospective study from the Mayo Clinic, the
median overall and disease-specific survivals for malignant
PPGLs were 25 and 34 years, respectively. These findings
indicate a slow disease course in a subgroup of patients.
Shorter survival was correlated with male sex, older age at
diagnosis, synchronous metastases, larger primary tumor
size, elevated dopamine levels and not undergoing primary
tumor resection (43). Patients with metastatic disease and
biochemically active tumors should remain a-blocked during
the follow-up period. Approximately 70% of patients with
malignant PPGLs develop bone metastases (mainly lytic). In
all patients with bone metastases, the use of antiresorptive
drugs (zoledronic acid every 6 months) may be considered to
avoid skeletal-related events (51). Locoregional guided ther-
apy, such as surgery and interventional radiology, may be
indicated to control pain and prevent fractures and spinal cord
compression.
Since the long-term survival is more than 10 years in a
subgroup of patients, and systemic therapies have substan-
tial toxicity, the initiation of systemic therapy for malignant
PPGL patients is justified mainly by tumor progression as
defined by RECIST (www.recist.com) (Table 4). The most
studied targeted therapy for malignant PPGLs is 131-I-MIBG
therapy. Because the structure of MIBG is similar to that of
noradrenaline, this isotope can be taken up by tumor cells
and cause radiation-induced cell death. Approximately 50%
of patients with metastatic lesions have a positive MIBG
uptake. Therefore, 131I-MIBG therapy is the first-line therapy
for this subgroup of patients. MIBG therapy is associated
with response rates ranging from 22 to 48% (50). A single
phase II trial included 50 patients with malignant PPGLs
who were treated with 131I-MIBG doses ranging from 492 to
1,160 mCi (52). The objective response rate was 22%. Disease
progression was found in 35% of patients after a year of
follow-up. The estimated 5-year OS rate was 64%. Toxicities
included grade 3 to 4 neutropenia (87%) and thrombocyto-
penia (83%). Two small studies of 90Y-DOTATOC and 177Lu-
DOTATOC showed tumor response rates of 8% and 17%,
respectively (53,54).
A retrospective study from the MD Anderson Cancer
Center reported an objective response rate of 25% using
cyclophosphamide and dacarbazine and the optional use of
vincristine or doxorubicin in 52 patients with malignant
PPGLs (55). In addition, a Japanese study reported a partial
or minimal tumor response in 8 (47%) out of the 17 patients
with malignant PPGLs treated with cyclophosphamide,
vincristine and dacarbazine (56). Temozolomide led to a
response rate of 33% in patients with malignant PPGLs (57).
Regarding molecular target therapy, patients with malignant
PPGLs treated with everolimus had no response (58,59).
Sunitinib promoted an objective response in 3 (18%) out of
17 malignant PPGL patients, although 43% of the patients
had improvement in blood pressure control. In this study,
most of the patients who exhibited a positive response to
sunitinib therapy had SDHB germline mutations (60).
Final remarks
Surgery is the only therapy that offers a cure for both
ACCs and PPGLs. High-risk ACC and PPGL patients should
be carefully monitored for recurrence. Among PPGL patients,
SDHB and SDHD mutation carriers have a significant risk of
recurrence. Since current treatments for both metastatic ACCs
and PPGLs are not associated with a good objective response
rate, trials of adjuvant therapies for high-risk patients might
be the most promising strategies to decrease recurrence and
improve OS. In addition, advanced metastatic ACCs and
PPGLs should be preferably addressed in prospective clinical
trials testing new molecular target agents.
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